Zika vaccine pre-clinical and clinical data review with perspectives on the future development

Stephen J. Thomas, Alan Barrett

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Zika is an arboviral illness caused by infection with the Zika flavivirus. Transmission most commonly occurs during a feeding event involving an infected Aedes mosquito or vertical transmission between an infected mother to her fetus. Infection outcomes range from asymptomatic to devastating neurologic injuries in children infected in utero. The recognition of Congenital Zika Syndrome prompted the declaration of an international health emergency and a call to rapidly develop medical countermeasures such as vaccines and therapeutics. A flurry of research and development activity in industry, government, non-governmental organizations, and academia during the most recent Zika epidemic (2015) stimulated the development of a number of vaccine candidate prototypes, generation of pre-clinical data, and the conduct of early phase human trials. The safety and immunogenicity of different vaccine platforms were demonstrated and mouse and non-human primate passive transfer studies hinted at the potential for clinical benefit in humans and defining an immune correlate of protection. A rapid decline in regional transmission, however, prevented the conduct a clinical endpoint efficacy trial. The pathway to licensure of a Zika vaccine remains unclear.

Original languageEnglish (US)
Pages (from-to)2524-2536
Number of pages13
JournalHuman Vaccines and Immunotherapeutics
Issue number10
StatePublished - Oct 2 2020


  • Zika
  • animal
  • human
  • vaccine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology


Dive into the research topics of 'Zika vaccine pre-clinical and clinical data review with perspectives on the future development'. Together they form a unique fingerprint.

Cite this